title: Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors.
authors.affiliation: Dermatology Department, Melanoma Unit, Hospital Clinic and IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
authors.forename: Gamze
authors.initials: G
authors.lastname: Erfan
authors.forename: Susana
authors.initials: S
authors.lastname: Puig
authors.forename: Cristina
authors.initials: C
authors.lastname: Carrera
authors.forename: Ana
authors.initials: A
authors.lastname: Arance
authors.forename: Lydia
authors.initials: L
authors.lastname: Gaba
authors.forename: Ivan
authors.initials: I
authors.lastname: Victoria
authors.forename: Adriana
authors.initials: A
authors.lastname: Garcia-Herrera
authors.forename: Llucia
authors.initials: L
authors.lastname: Alos
authors.forename: Josep
authors.initials: J
authors.lastname: Malvehy
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000139:chemically induced / Q000517:prevention & control*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced / Q000517:prevention & control*; D003875:Drug Eruptions / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects; D007636:Keratoacanthoma / Q000139:chemically induced / Q000517:prevention & control; D007645:Keratoderma, Palmoplantar / Q000139:chemically induced / Q000517:prevention & control; D055623:Keratosis, Actinic / Q000139:chemically induced / Q000517:prevention & control; D017492:Keratosis, Seborrheic / Q000139:chemically induced / Q000517:prevention & control; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors*; D010091:Oximes / Q000008:administration & dosage / Q000009:adverse effects; D010787:Photosensitivity Disorders / Q000139:chemically induced / Q000517:prevention & control; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D011728:Pyridones / Q000008:administration & dosage; D011744:Pyrimidinones / Q000008:administration & dosage; D012878:Skin Neoplasms / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects; D000077484:Vemurafenib
chemical_list: D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D011728:Pyridones; D011744:Pyrimidinones; D013449:Sulfonamides; D000077484:Vemurafenib; C560077:trametinib; D048493:Proto-Oncogene Proteins B-raf; D020929:Mitogen-Activated Protein Kinase Kinases; C561627:dabrafenib